SCHEMBL3100018

SCHEMBL3100018

C[C@H](NC(=O)C1(c2ccccc2)CCNCC1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
TP53 P04637 1/20 0.50
HTT P42858 1/20 0.50
OPRM1 P35372 1/20 0.50
HDAC1 Q13547 1/20 0.50
TACR1 P25103 1/20 0.46
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
MME P08473 1/20 0.44
HDAC4 P56524 2/20 0.44
ATM Q13315 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
RECQL P46063 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CTSL P07711 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102482 0.91 NPC1 (0.51) ALDH1A1TP53HTTOPRM1HDAC1
SCHEMBL7912225 0.91 ALDH1A1 (0.53) ALDH1A1TP53HTTOPRM1HDAC1
SCHEMBL7907628 0.91 NPC1 (0.51) ALDH1A1TP53HTTOPRM1HDAC1
SCHEMBL13092152 0.91 TACR1 (0.49) ALDH1A1TP53HTTOPRM1HDAC1
SCHEMBL7912422 0.88 ITGA4 (0.51) ALDH1A1TP53HTTOPRM1HDAC1
SCHEMBL6543233 0.87 ALDH1A1 (0.69) ALDH1A1HTTOPRM1HDAC1TACR1
SCHEMBL14491529 0.86 HDAC4 (0.60) ALDH1A1TP53HTTLMNAHPGD
SCHEMBL5358777 0.86 HDAC4 (0.60) ALDH1A1TP53HTTLMNAHPGD
SCHEMBL14491528 0.86 HDAC4 (0.60) ALDH1A1TP53HTTLMNAHPGD
SCHEMBL7902182 0.84 ALDH1A1 (0.55) ALDH1A1HTTOPRM1HDAC1TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 ALDH1A1 480/4885TP53 3137/4885HTT 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.